Erytech
ClosedHelping patients live longer, better.
Public · Lyon, France · Founded 2004 · $274.6M raised
- Headquarters
- Lyon
- Employees
- 51–200
- Founded
- 2004
- Business Model
- B2B
- Website
- erytech.com
- Total Funding
- $274.6M
- Last Round
- $144.0M Private EquityNov 2017
- Rounds
- 4
- Type
- Public
About
ERYTECH is a clinical-stage biopharmaceutical company that developed innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Founded in Lyon, France in 2004, the company focused on encapsulating therapeutic agents inside red blood cells to reduce toxicity and improve efficacy. ERYTECH was listed on the Nasdaq Capital Market and Euronext Paris. The company later merged with PHERECYDES to form PHAXIAM Therapeutics, which subsequently entered judicial restructuring in 2025.
Summary
Erytech is a Biopharmaceutical company based in Lyon, France, founded in 2004. It has raised $274.6M in total across 4 rounds, most recently a $144.0M Private Equity round in Nov 2017.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2020
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...